Case Report: Stent Thrombosis Associated With Non-Response to Clopidogrel Despite Co-Administration of Aspirin and Ibrutinib

Clicks: 1
ID: 314719
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #155 of 251 articles by views in European Heart Journal - Case Reports

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 251 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Managing atherosclerotic cardiovascular disease in individuals with chronic lymphocytic leukaemia (CLL) is complicated by the uncertain antiplatelet effect exerted by Bruton’s tyrosine kinase inhibitors. Concerns over increased bleeding risk with concurrent ibrutinib and dual antiplatelet therapy (DAPT) are balanced with the need to provide robust antiplatelet cover following percutaneous coronary intervention (PCI) and reduce the risk of stent-related complications. Case summary We describe a case of an 83-year-old patient with a background of stable CLL on ibrutinib. He was appropriately established on DAPT (clopidogrel and aspirin) prior to elective PCI. Post-procedure, the patient re-presented after six days with subacute stent thrombosis (SST). Platelet function tests demonstrated clopidogrel non-responder status, with high platelet reactivity to multiple agonists. He was switched to ticagrelor with excellent antiplatelet response and underwent repeat PCI. Discussion This case is the first description of SST in a patient on concurrent DAPT and ibrutinib. It highlights the need for appropriately robust P2Y12 inhibition despite bleeding concerns and ex vivo studies demonstrating some antiplatelet effect by ibrutinib. This case also highlights the role for platelet function testing to tailor antithrombotic regimens in complex and high-risk PCI patients.
Reference Key
openalex_W7162111983 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Omar Dirir, William A E Parker, Hazel Haley, Julian P. Gunn, Robert F. Storey
Journal European Heart Journal - Case Reports
Year 2026
DOI
10.1093/ehjcr/ytag352
URL
https://doi.org/10.1093/ehjcr/ytag352
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.